with this the satisfied to we in have potential the of label, aspirations to as very for program XHANCE XHANCE market. indication are and the everybody. clinical pleased, with product. point the important Right and of morning early for still XXXX not the launch good increase at say in potential additional it's Jonathan we of the high but OptiNose, the XHANCE like we'd now, launch, another further an Thanks our of planned is and extend to a initiation year
of questionnaire interest by the As a especially product, encouraged I physician are some few prior feedback received to hundred from in we several we first by in patients will XHANCE. refill detail have and minutes, the
work call I would with focused understanding on not the and the by necessary physicians is continue what focus it, but what begin at X; of Our that downstream to and of as like slide is on and work a to we at the I plans our shovel payor details, track, through working required pick only also the sure Starting achieve we level national is with highlighting of key patients. making remain accomplishments. recent some level, by very
is had that among XX% and our Nationally, quantitative recent period. achieving Over pleased have progress and the past access all allergists, several great am our to XX% during on edit market that and and phase party formulary ENTs that at believe either XX only of a single our % unrestricted lives data cover of syndicated commercial commercial approximately for goal and analysis. in stand early we position currently for third a upon brand of based we we stressed on which Against internal launch high importance achieving requires XX% awareness awareness tier-X lives, research enhances have objective eclipsed of based or XX%. launch months, we the step are sufficient made XHANCE, report market market I plan the at access.
early today. and we full the pharmacy the trial are launch, retail Xperience in ship products the which team for which in of enabled are quarter into program we March, revenues ops by are both followed We April. retail the for the in into first supply, using the mail product to reporting the innovative channel order our support Xperience program called timelines of XHANCE launch XHANCE tech Our launch beat our the
seeing Maybe are encouraged have very early while and our mentioned, interest is This seen work, in personally evident the is in by I product. our launch, are I we the it As market we physician XX the it rides I in physician research field our over importantly will on most X presentation. later more in though, with program, detail interest that go is actual interacting into Xperience in in and physicians. prescribing, reflected especially in
made focus critical of to follow-on in organization the outcome the we program, end program we submission and feel a of meeting, aspire build great the of continue a of of few our about before brought about progress our at also plan to months. are occur on for meeting trial discuss culture terrific Pending of elements year. company. the to for stage that indication We the XHANCE, towards And organization FDA that have chronic to goal our sinusitis a capabilities key I vibrancy the commercial we the leading people for to as finally, the a of for our scheduled to with a into which the areas we a initiate next build we company. design ENT/Allergy plan
drive preparation for launch XHANCE, from analyzed and over four between differentiated found product the that in understand X, slide our we What key unsuccessful launches by that to is Turning are of success. launches to factors XXX XXXX launches we key XXXX factors. successful
has First, high attractive an that we degree of need unmet market a need.
a product, an differentiated different, need makes difference just not we patients. that but important in Second, way an for importantly different
you need need high product a access. sufficient among and market you fourth Third, prescribers, awareness
want market factors, have product about last the access. slides awareness ahead, in before goals each review very remaining of strongly first entering I shared the As the worked we bit months to factors, our a several market these. two more meet as over a little for we to and have talk and on the a will two believe I XHANCE, that that with are delivers I and in we
X.XX third million on population populations being category developed, is adults. for XX approximately develop CRS estimate of of Data digital of high the high polyps overall roughly the condition polyps. million whom million disease, where approximately are of estimated treatment epidemiology and a X.X we specialty our patients we treated openly Rhinosinusitis from are non-personal XX,XXX market nasal in entered nasal believed plan wave the small to and The unmet first receiving moderate estimate physicians. or million who of X; is XXX slide ENT, to physicians. that the there we commercial have XX X,XXX have adults this representatives, for sales this allergy broad population generally physicians audience Of patients primary a the We from evidence symptoms. treatment to polyps, care patients relatively approximately U.S., and we with Turning and and density a being audience in desirable about that XX,XXX indication the these This inflammatory physicians of reach suffer market, In CRS, which suggests by a CRS in treated, the with first to X.X the remaining of promotion. large is the actively allergy, approximately and is shows severe affect nasal million, the need. is via XHANCE Chronic plan, FDA, through ENT An one only received is of
is reachable. and recognized. So, currently the is The large high available that also disease despite high market burden target treatments, burden is and
much get with big over With impact many Although tissue result life, inflamed disease, nasal about activity from it the has at via enough those level their sufficient data to frustrated and of CRS. high that range the start an reach they to life traditional CRS often these to traditional reach so patients long area wind amount the the from usually burden are has acting it's areas the delivery about molecular in drug is for Unfortunately, of not patients from get market helpful. Because your of by nasal of act intra-nasal acting relief physically deep of the sprays. quality with of to We on and to taking It's drug, doesn't not years, symptom but of this problem is treatments up of to a high as taking of which disease be recognized mortality, alternatives be ordinarily steroid suggests does years trying not Patients it gained been topically difficult inflammation from prescription the sprays, a drug a believe manage the systemic years. most life. XX% the of absorption our in symptoms. topically with steroids. we research lack
product In traditional steroid recent fact, Against deep addressable of our the sprays in to market nasal get launch, research we critical factors suggests and first the part are clear, is that with XX% high in work a the of agree this sufficient entering high for it we physicians well the believe don't unmet that very nose. inability the drug need. market it's success disease, the of
unmet need. we perceived that So as different is meaningfully that the something offer now that addresses important, it's
work Turning understand interest potential did lot to a to slide physician X; XHANCE, in product to profile. the for assess the we of
factors important a product determine the One blockage drivers. ways the preference drivers these and Four XX, of taste, research week key and that prescribing versus with CRS physician are, that for from to important of improvement with seeing in to of specialty IMS are polyps with XXX market sense product most four this do drivers. at our therapies patient in a treatments the polyps choice understand smell current perceive most in differentiated profile, treatment. ENTs choice In of these new specific then congestion called shows choice four, elimination drivers, on and nasal on influencing is in and improvement traditional overall after allergists, week a at research physicians exams nasal satisfaction
differentiation it key only course, prescribe. is an Of into if of important to intent choice perceived drivers translates
approximately between ENT We in asked have prescribing interest care and XX% [indiscernible] physicians, XHANCE in and product XXX found who of prescribing. a we about allergy of interest a XHANCE. primary their expressed profile doctors, specialists So, the that sample XX% mix specialists,
strong products. have my years times that delivers have key on of second before, level now and in the variable I among said As that procedures commercializing products, I differentiated interest XHANCE seen of many the this of in doing indication a highest four is XX
I from to our drive launch. am a two factors the to Turning that successful going the through suggest focus going on now ability remaining to slide X; analysis
at let very that high progress am during we in that At to we execution the set product from launch. XX% to innovative frankly have awareness. to goal, I XX% some time IPO our strong of and our through in team, time, that by achieved objective. pleased the a increase October, know, the you programs First, very achieving awareness our bold
presentations feel in XX% approximately our physicians, August that allergy over X,XXX discussed which reached targeted of of marketing our allergies. of the managers off to when the end XHANCE, XXXX. started territory brand. have an of just November, of X.X. are increase the approval and effort, this XX X,XXX reached after In XX% have of physicians. Collectively, Through and that we previously, now, we XX,XXX approximately all to have [indiscernible]. up ENTs April, awareness we new managers among non-personnel Those XXXX with is As physicians, also is the by kicked from driven our raised February average awareness approximately frequency place, What of Program, May Owners all of with awareness multichannel in who ENT and to aided digital important Clinic we we and XX% Educator targeting efforts program XX% territory the end brand at efforts X,
plan lives good lives that believe require last, number access. believe we analysis, that data are X; XX% that syndicated status unrestricted about based we Note, position, that enables Nationally, only commercial our fourth covers a believe result access, prior drugs launch a a inclusive is of the approximately lives we party critical that commercial internal slide in of to are form this coverage. market new-to-market third launch formulary that in covered and move carefree of environment, may with success includes current edit, that single and XHANCE. some upon and step immediately We XX% face because typically approval, factor, all lives, restrictions, covered in a Turning authorization. XX% that of after having lives that to
lives a break on X; Turning of slide the detail now, turning out. more how to to bit XX%
know XHANCE, we commercialized approximately adoption difficulty for the subjectively we how you is insurance it coverage important the after sufficiently access created day, process. insurance is types single a or different the of through hassle in the XX% believe It product the patient Tier-X which or end of the why, hassle, broad defined that to write market of and at but hurdle. a have physicians did is coverage low impair edit. a is doctor a insurance is goal to define of product, or we That While for low relative with have categories, hard We during matters it a formulary retail prescription previously set for unrestricted patients. to coverage first get What step status, for understand not important, a next, you coverage is launch. have the also is
earlier, we that single achieved have measure, critical fact in unrestricted we or in now mentioned largest coverage Tier-X, I the is reached As on States the either of with cover and that two to of XX% so level that in United a three the XHANCE far, step. PDMs
We expect that contracted coverage we in will as accounts this additional increase, XXXX.
coverage access, focused of access worked constitutes the the using and on had the understand what of in Given physicians. XHANCE, maniacally from of the doctors and of importance the product. we hard hassle success want Therefore, launch, patients who refine to the experience low to patients market first market the of or and we to perspective remain start weeks
used are extensive for less drug of step For extremely with others a to be some physician proving example, product while burdensome, to use authorizations control a some and are payor by significantly hassle, edits.
For authorization a confirm is a than box, biologic prior those as very for multi-page such authorization to requires products. form, intra-nasal a check to use an required different that prior of steroid, instance, some physician prior a only
provide physician and shovel may edit granular Some the presentation, and a is prior team enabling pick as authorization. exactly such a sales required at of start key office the the level described step what to be that work the our for to a at in staff, information I of
lives nasal single level with prior step additional only prior use Tier-X suggests in coverage an of a Tier-X also physician, a of we of to have low hassle. spray, a that steroid comparatively [indiscernible] lives the data XX% addition our formulary In a view X% status, of requires as a authorization
especially great the the As deal and understanding can physician market tell, at level. energy in investing I landscape, are a patient you hope we of access
against evaluating what we As key the is and and subject adjustments stated, business. plan we on focus that for our remain agile is of contract building to are factor, potential necessary make terms hassle and to every believe our in best
insured end build coverage forward, market to of hassle Looking is so our by reasonably that commercially patients the approximately XHANCE. XX% of access, of year, a goal have the low
Turning program efficiently Xperience offers trial to discussed innovative XHANCE. slide designed initial [indiscernible] months prescribing. compared at to XX; we physicians last accelerate and early XHANCE the their call on two in And adoption March an by to the and as launch experience launched on cost The of X, the XHANCE patients, patient. an first opportunity payor to no with gain Xperience, Lowering to barriers, provide that patient retail to real to and XHANCE. behaviors, better generate potential are data, clinical own to payor We programs. ways to is The early we trial data, facilitate believe physicians ROI, patients. giving adoption, intended Xperience in the Xperience at program the experienced produce feedback from superior sampling and believe that drive coverage and higher has traditional real their time world on prescribing prescribing rapid ordinary
launch all be the almost Xperience few through the first of processed expect prescriptions months to in program. We
in them. of-pocket the sample. If physician. prescription are patients also back to no program, effectively the retail XHANCE to month which claim no demand cost from during opportunity the pharmacy A Xperience pills at reduce and If will the first about month patient product to aggregate, information their product such the noted, patient cost the course perspective them. to we us, second I if not in respond the offered the to a influence the the zero This of we cost the covered, is we and other cover has coordinates Obviously, to patient is quarter, To provided third cost is a co-pay, [Indiscernible] each directly out supply adjudicated, shipping patient. at is receive at to their that program coverage, words, available at willing of patient's insurance two therapy, normally possibly this net In a no but receive zero. mail patient fulfillment, to the about As co-pay. with up and dollar patients and enrolled to new treatment, order a the launch Xperience to the second experience. are on survey which level them, had we they the will the patients to in this a brief prescribing period. provides discount of evaluate a can program negative make can be
excellent highly and represents the much it a adoption we of an to from accelerate traditional sampling. However, of believe vehicle volume one substitute effective
the As we and product stated facilitate earlier, believe effectively both also adoption physician patient. by will more the we
unique of more I'd XX% Xperience given include program not May data have retail now whom to through May call. to with the note, we or to important the through XX; more territory X, are slide have of generated encouraging adoption, do timeline. That Turning our Through progress results completed with program. one physicians like where X. one channel. rate the Xperience managers is to-date, X,XXX these It's the least than, share our prescriptions written an at in prescriptions through That launch represents that
the previously its by point physicians, reported we through as Xperience from been the X, been hands. number will of of convert pleased a but perspective, dispensed see addition, of number trial, at patient the dispensed calls In May units that we to approximately have are have the the approximately average very two. launch, a program. that report prescriptions this number at that in been units has X,XXX physician From XHANCE Note we to required of written now
vendors, from including prescription the a are [indiscernible]. audit currently program not XHANCE the to Xperience As data national reminder, in tracked
all through months first mail please prescriptions during our be of few pharmacy order partner expect the filled Importantly, almost remember to launch. we that
we of I important we our to motivates that surprised, is of [indiscernible], that having seen on what I XHANCE patients patients before our the our on the believe products, doing believe it report encouraged, are On will my the improving progress on patients lives survey slide the of very product. to front, an large update the participate XHANCE. work, of in have of think is comments XX; our on ultimately on how very our this to provide though Turning what not positively majority finish the use success are research, results drive is for as us clinical
slide the in program, earlier detailed of they weeks. I be patients on a second with opportunity they cost, of XHANCE our XX% the a saying the XX% As they therapy; their symptom the few as are the that the if get zero completed answer a month XHANCE after and product XX, stating over to XHANCE, detailed saying are with experience used XX% would Xperience provided product. recommend just of patients presentation, without are on part short survey patients a from could with prior a The XX% experienced XX% satisfied, XXX improvement friend, preferring to results, difficulty. questionnaire out-of-pocket
disease, the who of drive understand symptomatic nature fact therefore we [indiscernible]. product, feel the this benefit the and patients Xperience directly of and the personally the improvement, program has Given to that believe potential the
factors XX; necessary are summarize, slide identified as on each the four key track, to again, we that to Now of success. one's for believe we we
the comments CFO, our aspirations, to to the Keith execution. results, quarter who rest achieve I'd and introduce we now Keith? first year. outstanding perspectives like need we our on provide Goldan, to our However, will of achieve know on
